Assignee
EUTILEX CO LTD
KR·23 granted patents·12 pending applications·52 citations·filing 2015–2023
Top patents by PatentIndex Score
35 records- 0196US10174122B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2018·Granted Jan 8, 2019·23 cites·15 claims
- 0295US9862775B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2015·Granted Jan 9, 2018·15 cites·9 claims
- 0390US10233254B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2017·Granted Mar 19, 2019·4 cites·18 claims
- 0484US10919972B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2018·Granted Feb 16, 2021·1 cites·2 claims
- 0584US10626183B2IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereofEUTILEX CO LTD·Filed 2019·Granted Apr 21, 2020·2 cites·30 claims
- 0683US11013765B2Chimeric antigen receptor that binds HLA-DR and CAR-T cellEUTILEX CO LTD·Filed 2019·Granted May 25, 2021·2 cites·15 claims
- 0783US10774151B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2020·Granted Sep 15, 2020·1 cites·5 claims
- 0882US10919976B2IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereofEUTILEX CO LTD·Filed 2019·Granted Feb 16, 2021·1 cites·4 claims
- 0980US10801011B2Methods for isolating and proliferating autologous cancer antigen-specific CD8+ T cellsEUTILEX CO LTD·Filed 2017·Granted Oct 13, 2020·1 cites·8 claims
- 1079US10570371B2Methods for isolating and proliferating autologous cancer antigen-specific CD8+T cellsEUTILEX CO LTD·Filed 2018·Granted Feb 25, 2020·1 cites·15 claims
- 1178US10927183B2Anti-human VSIG4 antibodies and uses thereofEUTILEX CO LTD·Filed 2020·Granted Feb 23, 2021·1 cites·28 claims
- 1274US11053298B2Epitope for switching to TH2 cell and use thereofEUTILEX CO LTD·Filed 2018·Granted Jul 6, 2021·0 cites·7 claims
- 1373US11859004B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Jan 2, 2024·0 cites·8 claims
- 1473US11072646B2Epitope for switching to TH1 cell and use thereofEUTILEX CO LTD·Filed 2018·Granted Jul 27, 2021·0 cites·6 claims
- 1573US10851151B2Epitope for switching to TH17 cell and use thereofEUTILEX CO LTD·Filed 2017·Granted Dec 1, 2020·0 cites·17 claims
- 1670US2024101678A1Hla-dr car-t compositions and methods of making and using the sameEUTILEX CO LTD·Filed 2023·Application pending·0 cites
- 1769US11396555B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2019·Granted Jul 26, 2022·0 cites·11 claims
- 1865US2021277139A1Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereofEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 1964US11951130B2Chimeric antigen receptor that binds HLA-DR and CAR-T cellEUTILEX CO LTD·Filed 2021·Granted Apr 9, 2024·0 cites·20 claims
- 2064US11905334B2Anti-human VSIG4 antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Feb 20, 2024·0 cites·15 claims
- 2163US11395836B2Cancer antigen specific cytotoxic T cellEUTILEX CO LTD·Filed 2019·Granted Jul 26, 2022·0 cites·14 claims
- 2260US2021401885A1Cancer antigen specific cytotoxic t cellEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 2357US12559538B2PD-1 polypeptide variantsEUTILEX CO LTD·Filed 2021·Granted Feb 24, 2026·0 cites·56 claims
- 2455US12331116B2Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereofEUTILEX CO LTD·Filed 2022·Granted Jun 17, 2025·0 cites·27 claims
- 2554US12122845B2Anti-HER2/anti-4-1BB bispecific antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Oct 22, 2024·0 cites·25 claims
- 2654US2020138859A1Har-nds-derived stem cells, method for separating same, and use thereofEUTILEX CO LTD·Filed 2019·Application pending·0 cites
- 2753US2025270320A1Anti-pd-1 antibody and uses thereofEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 2852US2023242607A1Il-2 variantsEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 2951US2024016837A1T-cell receptor binding to mr1, and use thereofEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 3051US2020165342A1Hla-dr car-t compositions and methods of making and using the sameEUTILEX CO LTD·Filed 2018·Application pending·0 cites
- 3149US10471097B2HAR-NDS-derived stem cells, method for separating same, and use thereofEUTILEX CO LTD·Filed 2015·Granted Nov 12, 2019·0 cites·8 claims
- 3249US2023151113A1Gpc3 car- t cells secreting il-18 and methods of making and using the sameEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 3349US2023146706A1Gpc3 car- t cell compositions and methods of making and using the sameEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 3448US2020172866A1Method of preparing and cryopreserving cancer antigen-specific cd8+ t cellsEUTILEX CO LTD·Filed 2019·Application pending·0 cites
- 3547US2022249565A1Chimeric antigen receptor with 4-ibb costimulatory domainEUTILEX CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EUTILEX CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →